PD12-05 LONG-TERM LOCAL ADVERSE EFFECTS OF PROSTATE CANCER TREATMENT - RESULTS FROM A POPULATION-BASED STUDY (2014)

You have accessJournal of UrologyProstate Cancer: Localized I1 Apr 2014PD12-05 LONG-TERM LOCAL ADVERSE EFFECTS OF PROSTATE CANCER TREATMENT - RESULTS FROM A POPULATION-BASED STUDY Sigrid Carlsson, Linda Drevin, Anders Widmark, Ingela Franck Lissbrant, David Robinson, Eva Johansson, Pär Stattin, and Per Fransson Sigrid CarlssonSigrid Carlsson More articles by this author , Linda DrevinLinda Drevin More articles by this author , Anders WidmarkAnders Widmark More articles by this author , Ingela Franck LissbrantIngela Franck Lissbrant More articles by this author , David RobinsonDavid Robinson More articles by this author , Eva JohanssonEva Johansson More articles by this author , Pär StattinPär Stattin More articles by this author , and Per FranssonPer Fransson More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.977AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The rates of long-term local adverse effects of prostate cancer (PCa) treatment remain poorly defined. The purpose of this study was to assess sexual, urinary and bowel function ten years after PCa diagnosis. METHODS In 2011, we identified 6 005 PCa survivors diagnosed between 1997 and 2002 who were ≤70 years at diagnosis, with local or locoregional disease in the National Prostate Cancer Register (NPCR) Sweden. Local adverse effects were evaluated with a validated self-reported questionnaire and 1 000 PCa-free controls matched for age and county of residence received the same questionnaire. RESULTS Response was obtained from 3 933 cases (65%) and 459 (46%) controls. After a median time of 11.8 years (IQR 10.8-13.2) post diagnosis, cases experienced adverse effects on sexual, urinary and bowel function; with 84% experiencing erectile dysfunction or being sexually inactive, 23% reporting urinary leakage and 13% having bowel disturbances. Compared with PCa-free controls, radical prostatectomy was associated with increased risk of urinary incontinence (age-adj. OR 5.46 [95% CI 3.63-8.60]) and use of pads to protect urinary leakage. Radiotherapy was associated with urgency symptoms (OR 1.75 [95% CI 1.34-2.28], whereas radical prostatectomy decreased these symptoms (OR 0.77 [95% CI 0.61-0.96]). Radiotherapy as a single or multimodal treatment increased the risk of bowel dysfunction (OR 4.96 [95% CI 3.27-7.75] for radiotherapy alone). Men who had received multi-modal treatment, in particular regimens including hormonal treatment, had a higher rate of adverse effects, e.g. radical prostatectomy followed by radiotherapy and hormones was associated with an OR of erectile dysfunction of 15.44 (95% CI 7.11-40.50) as compared to controls. (Figure 1) CONCLUSIONS The proportion of men who suffer long-term local adverse effects after PCa treatment is substantial. Men who received multi-modal treatments were at particularly high risk. © 2014FiguresReferencesRelatedDetailsCited byMeng M (2018) Editorial CommentaryUrology Practice, VOL. 2, NO. 6, (358-358), Online publication date: 1-Nov-2015. Volume 191Issue 4SApril 2014Page: e348 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Sigrid Carlsson More articles by this author Linda Drevin More articles by this author Anders Widmark More articles by this author Ingela Franck Lissbrant More articles by this author David Robinson More articles by this author Eva Johansson More articles by this author Pär Stattin More articles by this author Per Fransson More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...